The San Diego Bowl Game Association’s board of directors has elected Dennis DuBard president of the nonprofit in 2023. DuBard succeeds Cherry Park.
The association has overseen the annual Holiday Bowl football game since 1978.
In February of 2022, the organization announced it also has assumed the role as the region’s sports commission – Sports San Diego. In February of this year, it added an early season college basketball tournament to its portfolio – the Rady Children’s Invitational, which tips off this Thanksgiving.
“The San Diego Bowl Game Association is considerably expanding its scope of work for the region, and therefore will be generating considerably larger impacts for our community,” said. DuBard, a 30-year U.S. Navy veteran who retied in 2007 at the rank of captain after accumulating over 3,000 hours flying helicopters and fixed-wing aircraft.
Following his service in the Navy, DuBard worked in the defense industry for over 14 years, first as an analyst at Whitney Bradley & Brown, Inc., and 12 years with General Dynamics NASSCO as a communications and government relations executive. He retired from NASSCO in December 2021.
Other 2023 elected officers for the San Diego Bowl Game Association include: Jackie Reed, president-elect; Shelley Zimmerman, secretary; and John Finkenberg, treasurer. Newly appointed members of the 21-member board of directors include Noreen Ippolito and Lynn Palmer.
+++
San Diego-based AnaptysBio, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, has appointed Rita Jain, M.D., to the company’s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the AnaptysBio Board.
“Rita is a recognized leader in rheumatology with extensive drug development expertise across a wide range of therapeutic areas across autoimmune and inflammatory diseases that strongly complements AnaptysBio’s Board experience,” said Daniel Faga, interim president and chief executive officer of AnaptysBio. “Importantly, Rita has been part of multiple biopharma companies at times of rapid growth and strategic transition. Her insights will be invaluable to us as we continue to focus our business on advancing immune cell modulators for people living with autoimmune and inflammatory diseases.”
“I am excited to join AnaptysBio,” Dr. Jain said. “Their portfolio of best-in-class immune cell modulating antibodies have the potential to address significantly underserved patient populations.”
Dr. Jain is a rheumatologist and currently serves on the boards of Provention Bio, Inc. and Celldex Therapeutics, and serves on the supervisory board of AM Pharma.
+++
Nichole Mayer and Melissa Gonzalez, financial professionals from San Diego, traveled to Washington, D.C., to participate in the inaugural Women’s Fly-In hosted by the National Association of Insurance and Financial Advisors.
